Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01433263 · ClinicalTrials.gov registry record · Phase 2
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT01433263 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 57 participants.
The verdict
NCT01433263, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
Interventions
- DRUG Placebo
- DRUG BYM338 active drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01433263
The ClinicalTrials.gov registry entry for NCT01433263 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01433263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01433263 about?
NCT01433263 is a clinical study titled "Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas". A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
What is the current status of trial NCT01433263?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2011-08. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01433263?
The interventions under investigation include: Placebo (DRUG), BYM338 active drug (DRUG).
Who is sponsoring clinical trial NCT01433263?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.